Jefferies has initiated coverage on Sai Life Sciences with a ‘Buy’ rating and a Rs 1,300 target price, citing its integrated ‘follow-the-molecule’ model and strong growth outlook. The brokerage highlighted the company’s healthy pipeline, global presence, and clean balance sheet as key investment drivers, projecting significant upside potential.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets